Evidence map›Paper›PMID 41266678›Full record

ArticleInfectious diseases and therapy2026

Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial.

Yueming Shao, Xinping Yang, Jianhua Yu, Xicheng Wang, Jiangrong Wang, Mei Liu, Zongxing Yang, Jie Han, Renfang Zhang, Li Liu and 13 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05122754 (Switching From Tenofovir Disoproxil Fumarate-based Antiretroviral Therapy Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virally Suppressed Adults With HIV-1 Infection), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05122754 phase4unknown statusnot on this map

Switching From Tenofovir Disoproxil Fumarate-based Antiretroviral Therapy Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virally Suppressed Adults With HIV-1 Infection

TypeinterventionalSponsorShanghai Public Health Clinical CenterRan2021 to 2024Enrolled150ConditionsHIV-1-infectionArmsB/F/TAF, TDF-based triple ART regimen switching to B/F/TAF
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yueming Shao *Department of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xinping Yang *Department of Infectious Diseases, Yunnan Provincial Hospital of Infectious Disease/Yunnan AIDS Care Center, Kunming, China.
Jianhua Yu *Department of Infectious Disease, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Xicheng WangDepartment of Infectious Diseases, Yunnan Provincial Hospital of Infectious Disease/Yunnan AIDS Care Center, Kunming, China.
Jiangrong WangDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Mei LiuDepartment of Infectious Diseases, Yunnan Provincial Hospital of Infectious Disease/Yunnan AIDS Care Center, Kunming, China.
Zongxing YangDepartment of Infectious Disease, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Jie HanDepartment of Infectious Disease, Affiliated Hangzhou Xixi Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Renfang ZhangDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Li LiuDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yinzhong ShenDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Meiyan SunDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Luling WuDepartment of Endoscopy, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhihang ZhengBiotherapy Clinical Research Center, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, China.
Yang TangDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Junyang YangDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Zhenyan WangDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Tangkai QiDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Shuibao XuDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jingna XunDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jianjun SunDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Wei SongDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jun ChenDepartment of Infection and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. qtchenjun@163.com.ORCID http://orcid.org/0000-0002-3850-4875

Funding

Gilead Sciences CO-US-380-5483Shanghai Public Health Clinical Center Grant Number KY-GW-2025-12Shanghai Public Health Clinical Center RCJJ2025-10
6 · The paper itself

Abstract

introductionTenofovir disoproxil fumarate (TDF)-based antiretroviral therapy regimens remain one of the first-line treatments in many countries. We assessed the changes of bone mineral density (BMD) in people with HIV (PWH) who had early switch from TDF-based regimens to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).

methodsThis 48-week, multicenter, randomized, open-label clinical trial recruited adult PWH on TDF-based regimens with virological suppression for at least 24 weeks. Participants were randomly assigned (1:1) to immediately switch to B/F/TAF (immediate switch group) or switch after 24 weeks (deferred switch group). The primary endpoint was the median percentage change [interquartile range (IQR)] in BMD from baseline to week 48.

resultsBetween December 17, 2021 and February 21, 2023, 150 PWH were randomly assigned to immediate switch group (n = 75) or deferred switch group (n = 75). At week 48, no significant difference in BMD changes of the spine was observed at week 48 [3.30% (IQR 1.19, 5.47) vs. 2.84% (0.51, 5.00); P = 0.199]. The increase in hip BMD was greater in the immediate switch group than deferred switch group [median percentage change, 2.05% (0.20, 4.12) vs. 0.88% (- 0.52, 3.15); P = 0.035]. Viral suppression at week 48 was noted in 71 (94.6%) participants assigned to the immediate switch group and in 67 (89.3%) assigned to the deferred switch group. Similar rates and severity of adverse events were observed in both groups, with no serious adverse events reported.

conclusionsWhile both immediate and deferred switch from TDF-based regimens to B/F/TAF maintained virological suppression, early switch resulted in better improvement of BMD in the hip joint. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov (NCT05122754).

Indexed as

Bone healthIntegrase strand-transfer inhibitorNon-nucleoside reverse transcriptase inhibitorNucleotide reverse transcriptase inhibitorOsteopeniaOsteoporosisProtease inhibitor

Identifiers

PMID41266678
PMCPMC12783487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.